We upgrade our recommendation on Accuray Incorporated (ARAY) to Outperform following our assessment of its healthy second-quarter fiscal 2011 results and increased visibility on the stock. We are upbeat about the compelling prospect in radiation oncology rendered by the company’s impending acquisition of rival TomoTherapy (TOMO). Second quarter earnings per share of 7 cents comfortably [...] (ARAY) Accuray Analyst Lifts Shares to Outperform